About Us
Naleya Genomics Indonesia (NGI) is a BGI Genomic joint venture company focused on the analysis and interpretation of genomic data and biotechnology-based genomic health screening to assist in the development of medical therapies and disease prevention. The company uses the latest technology and algorithmic analysis to identify genetic variants that have the potential to affect health and provides individualized solutions for each patient.
We provide the right solutions regarding the importance of prevention related to personal health which is currently the focus of the government in transforming the health of the Indonesian people. We work closely with medical professionals and private health support institutions such as hospitals, clinics and private physician practices to improve the quality of genomic screening services in Indonesia and help patients understand their genetic information and how it can affect their health.
Our current development focus in Indonesia is to become a pioneer and incubator of the latest biotechnology-based genomic testing support services that are affordable to the people of Indonesia. We are supported by a modern laboratory infrastructure that creates new ideas for better solutions for the Indonesian healthcare system. We are committed to providing customer satisfaction and comfort through wholehearted service.
